Hims & Hers Health Faces Securities Class Action After FTC Lawsuit Leads to Stock Plunge

Recent Legal Troubles for Hims & Hers Health

Hims & Hers Health, Inc. (NYSE: HIMS) has recently found itself at the center of a substantial securities class action lawsuit. This impending legal challenge arises from a sweeping complaint filed by the Federal Trade Commission (FTC) that alleges significant business misconduct by the company. Investors are now watching closely as these developments unfold, especially after a dramatic drop in the company's stock prices.

On July 29, 2026, Hims & Hers experienced a shocking stock decline, losing $4.32 per share, which represents a staggering 14.7% decrease in value. This sudden dip translated to a loss exceeding $970 million in market capitalization in just one day. The catalyst for this drastic market reaction was a comprehensive FTC investigation that uncovered potential deceptive practices related to the sharing of health data and the execution of subscription models without proper consent.

Allegations Against Hims & Hers Health

The FTC's complaint points to several concerning points regarding Hims’ business operations. Firstly, it accuses the company of sharing sensitive consumer health information with third-party advertising platforms, defying their marketing promises of strict privacy protections and confidentiality. Notably, firms like Meta Platforms and Snap are named in the complaint as recipients of this data.

Additionally, the lawsuit highlights procedural issues concerning Hims' subscription model. It alleges violations of the Restore Online Shoppers' Confidence Act (ROSCA) by automatically enrolling customers into recurring subscription services without their informed consent. Particularly troubling is the practice of charging customers for prescriptions immediately after they submit their intake forms, prior to any consultation with a medical provider. Regulatory analysts suggest that such practices could result in heightened enforcement actions, potentially leading to significant penalties for Hims.

Legal Response and Investment Implications

In response to the allegations, Hagens Berman, a law firm representing the interests of investors, is actively investigating the situation. They invite investors who have sustained significant losses due to the allegations surrounding Hims to come forward and submit their experiences. The firm is focusing on assessing whether Hims has misled investors regarding its internal controls and the financial implications of the alleged misconduct.

Additionally, the insights from Hagens Berman indicate that there might be a broader impact on investor sentiment regarding telehealth practices and compliance with federal regulations. The outcome of this lawsuit could serve as a bellwether for the telehealth industry, highlighting the importance of transparency and consumer protection in business practices.

What's Next for Hims & Hers Health?

As the class action lawsuit progresses, stakeholders are keenly aware of the potential ramifications for Hims & Hers. The specified deadline for submitting claims as a lead plaintiff is November 2, 2026, marking a critical moment for both the company and its investors. Investors are encouraged to keep a close eye on further developments.

The firm also underscores the importance of whistleblower protections, suggesting that individuals with non-public information regarding Hims may have valuable insights to contribute to the investigation. Protecting consumer rights in the health sector remains essential, and this case might have lasting consequences on how such companies operate moving forward.

With the spotlight now firmly on Hims & Hers Health, it remains to be seen how they will navigate these legal waters and ensure compliance with regulatory expectations while restoring investor confidence.